Auditory Neuropathy: The Resonate Program

The Resonate™ program provides genetic testing, and optional genetic counseling, to eligible individuals with a clinical diagnosis of auditory neuropathy, or a medical history consistent with auditory neuropathy, at no cost to the healthcare provider, program participant, or participant's insurance. This program is sponsored by Akouos, Inc.

The genetic testing for eligible individuals participating in this program is performed at Blueprint Genetics and optional genetic counseling services to review genetic testing results are provided through the program by InformedDNA, a national provider of genetic counseling in the United States.

How to order

- Complete the program's custom paper requisition form and return it to Blueprint Genetics; for assistance with ordering, contact support.us@blueprintgenetics.com.
- Obtain the signed Genetic Testing Program Informed Consent from the program participant or their parent/legal guardian.
- Whether the sample collection occurs in the healthcare provider's office or is performed remotely, the participant's sample and the signed consent form should be placed into the Blueprint Genetics test kit. The kit should be placed into the prepaid FedEx®-envelope.
- Schedule a FedEx® pickup at www.fedex.com.
- The ordering healthcare provider will be notified by email when the results are are available, on average, in 3-4 weeks' time.

We are here to help
For further assistance, please contact
support.us@blueprintgenetics.com
www.blueprintgenetics.com

Benefits of a genetic diagnosis

- A genetic diagnosis can lead to better insight to help guide medical management and decision-making, as well as determine potential eligibility for clinical studies or future clinical trials.
- Access to Blueprint Genetics Comprehensive Hearing Loss and Deafness panel, one of the most comprehensive available tests of its kind, may provide program participants the ability to receive a genetic diagnosis.
- Genetic counseling to review results is available through the program by InformedDNA, at no cost to the healthcare provider, participant, or participant's insurance. These optional sessions are provided via telehealth.

Eligibility

The individual

- Has a current or prior clinical diagnosis of auditory neuropathy or a medical history consistent with auditory neuropathy. Auditory neuropathy is a hearing disorder characterized by an absent or abnormal auditory brainstem response (ABR) with preservation of otoacoustic emissions (OAEs) and/or cochlear microphonics (CMs).
- Has OAE and/or CM present, or previously present, with absent or abnormal ABR.
- Does not have evidence of a syndromic medical history.
- Must live in the United States in order to access the optional genetic counseling.

AKOUOS

InformedDNA® Genetics, Decoded.

Blueprint Genetics

Increased diagnostic yield with a comprehensive genetic test

High-quality genetic testing

Blueprint Genetics 239-gene Comprehensive Hearing Loss and Deafness Panel is one of the most comprehensive available tests to potentially determine the underlying cause of genetic forms of hearing loss. The test includes analysis of:

- High-resolution copy number variants (CNVs)
  - CNVs are identified in approximately 20% of all deafness-causing genes
- The entire mitochondrial (mt) genome
  - 1% to 3% of non-syndromic hearing loss is associated with mtDNA mutations
- 112 known pathogenic deep intronic variants

Informed consent and data sharing

- The genetic testing provider, Blueprint Genetics, will only share deidentified patient data with Akouos, Inc. These data are limited to the clinical diagnosis or diagnoses, year of birth, sex, and genes and variants associated with a clinical diagnosis of auditory neuropathy. No identifiable information or raw sequence data from program participants will be shared.
- We may share information about the ordering healthcare provider, such as contact information with Akouos, Inc.
- Blueprint Genetics may use the samples and data internally to improve the understanding and diagnostics of genetic forms of hearing loss. No samples or identifiable research data will be shared with third parties without express permission from the participant.
- Eligible individuals who wish to participate in the genetic testing program are required to provide Informed Consent.
- Information from optional genetic counseling sessions is not shared with Akouos, Inc.

Optional genetic counseling

- During the test requisition process, the healthcare provider will have the opportunity to request genetic counseling through the program by InformedDNA to help participants understand their genetic testing results at no cost to the healthcare provider, participant, or participant's insurance.
- This is an optional service and only available in the United States.
- The sessions by InformedDNA include a comprehensive review of genetic testing results, including interpretation of identified genetic variants, a review of medical and family history, and medical management recommendations (if applicable).
- Following the session, program participants and healthcare providers receive a formal summary report prepared by the genetic counselor. The formal summary report, including any information from the genetic counseling sessions, is not shared with Akouos, Inc.

Comprehensive Hearing Loss and Deafness Panel

239 genes

112 known pathogenic deep intronic variants included

Importance of CNVs:

CNVs identified in approximately **20%** of all deafness-causing genes

Mitochondrial genome

1 to 3% of nonsyndromic hearing loss is associated with **mtDNA** mutations

An estimated **60%-80%** of congenital hearing loss is genetic in origin

AKOUOS

InformedDNA® Genetics, Decoded.

Blueprint Genetics